Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

10:16
12/01/16
12/01
10:16
12/01/16
10:16

bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray

Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
12/01/16
WELS
12/01/16
NO CHANGE
WELS
bluebird bio data positive, says Wells Fargo
After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.

TODAY'S FREE FLY STORIES

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

SDR

SandRidge Mississippian Trust II

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Hot Stocks
SandRidge Mississippian Trust II receives NYSE notice on listing standards »

SandRidge Mississippian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
01/22/18
01/22
09:15
01/22/18
09:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HAL

Halliburton

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
Halliburton says expects improved utilization to drive margin growth »

Sees boosting frack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
FirstEnergy receives $2.5B equity investment »

FirstEnergy announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DNKN

Dunkin' Brands

$64.56

-0.53 (-0.81%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Upgrade
Dunkin' Brands rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.85

-0.54 (-0.41%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Recommendations
Visteon analyst commentary  »

Visteon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.75

0.65 (1.00%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Conference/Events
Mellanox management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

IOVA

Iovance Biotherapeutics

$10.70

1.075 (11.17%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Recommendations
Iovance Biotherapeutics analyst commentary  »

Iovance Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:11
01/22/18
01/22
09:11
01/22/18
09:11
Hot Stocks
Halliburton says International business started to recover in 2H17 »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

09:10
01/22/18
01/22
09:10
01/22/18
09:10
General news
Treasury Option Action: doubly bullish positioning »

Treasury Option Action:…

GRA

W.R. Grace

$73.71

0.92 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Hot Stocks
W.R. Grace licenses UNIPOL PP process technology to Poland's Grupa Azoty »

W. R. Grace has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 02

    Mar

PRI

Primerica

$104.50

1.3 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Recommendations
Primerica analyst commentary  »

Primerica price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

ARCT

Arcturus Therapeutics

$9.15

-0.15 (-1.61%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Initiation
Arcturus Therapeutics initiated  »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$52.15

0.45 (0.87%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Upgrade
Meritage Homes rating change  »

Meritage Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

INSG

Inseego

$1.66

-0.01 (-0.60%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Hot Stocks
Inseego says board adopts NOL rights plan »

Inseego Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

XRX

Xerox

$31.80

0.43 (1.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Icahn, Deason call on Xerox to explore strategic alternatives, replace CEO »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:05
01/22/18
01/22
09:05
01/22/18
09:05
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:05
01/22/18
01/22
09:05
01/22/18
09:05
Earnings
Wynn Resorts reports Q4 adjusted EPS $1.40, consensus $1.38 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FFBC

First Financial Bancorp

09:04
01/22/18
01/22
09:04
01/22/18
09:04
Upgrade
First Financial Bancorp rating change  »

First Financial Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVAX

Dynavax

, GSK

GlaxoSmithKline

$38.20

0.03 (0.08%)

09:04
01/22/18
01/22
09:04
01/22/18
09:04
Recommendations
Dynavax, GlaxoSmithKline analyst commentary  »

Dynavax has sold off 30%…

DVAX

Dynavax

GSK

GlaxoSmithKline

$38.20

0.03 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 26

    Feb

  • 25

    Mar

  • 23

    Apr

EGP

EastGroup Properties

$84.88

1.43 (1.71%)

09:04
01/22/18
01/22
09:04
01/22/18
09:04
Upgrade
EastGroup Properties rating change  »

EastGroup Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ENZ

Enzo Biochem

$7.96

0.17 (2.18%)

09:04
01/22/18
01/22
09:04
01/22/18
09:04
Hot Stocks
Enzo Biochem announces validation of cervical cancer biomarker detection test »

Enzo Biochem announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.